Eiger BioPharmaceuticals logo

Eiger BioPharmaceuticalsNASDAQ: EIGR

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

30 January 2014

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$12.58 M
-97%vs. 3y high
20%vs. sector
-vs. 3y high
-vs. sector
-118%vs. 3y high
14%vs. sector
-97%vs. 3y high
20%vs. sector

Price

regular market | Mon, 30 Sep 2024 13:30:00 GMT
$8.50(0.00%)

Dividend

No data over the past 3 years
$3.80 M$5.55 M
$3.80 M-$13.45 M

Analysts recommendations

Institutional Ownership

Included in screeners

No data

EIGR Latest News

Healthcare stocks fade as obesity-drug optimism fades
Market Watch01 April 2024 Sentiment: NEUTRAL

Healthcare companies fell sharply Monday as ebullience about a new class of weight control drugs subsided.

Why Is Eiger BioPharmaceuticals (EIGR) Stock Down 31% Today?
InvestorPlace13 September 2023 Sentiment: NEGATIVE

Eiger BioPharmaceuticals (NASDAQ: EIGR ) stock is falling on Wednesday after the biopharmaceutical company halted a Phase 3 clinical trial. According to a press release from the company, it has discontinued its Phase 3 LIMT-2 study.

Eiger BioPharmaceuticals: Wall Street Has High Expectations For Faltering Battleground Stock
Seeking Alpha16 June 2023 Sentiment: POSITIVE

Wall Street Analysts have high expectations for Eiger. Eiger has a modest pipeline. Expect near term data to impact the stock in a big way.

What type of business is Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

What sector is Eiger BioPharmaceuticals in?

Eiger BioPharmaceuticals is in the Healthcare sector

What industry is Eiger BioPharmaceuticals in?

Eiger BioPharmaceuticals is in the Biotechnology industry

What country is Eiger BioPharmaceuticals from?

Eiger BioPharmaceuticals is headquartered in United States

When did Eiger BioPharmaceuticals go public?

Eiger BioPharmaceuticals initial public offering (IPO) was on 30 January 2014

What is Eiger BioPharmaceuticals website?

https://www.eigerbio.com

Is Eiger BioPharmaceuticals in the S&P 500?

No, Eiger BioPharmaceuticals is not included in the S&P 500 index

Is Eiger BioPharmaceuticals in the NASDAQ 100?

No, Eiger BioPharmaceuticals is not included in the NASDAQ 100 index

Is Eiger BioPharmaceuticals in the Dow Jones?

No, Eiger BioPharmaceuticals is not included in the Dow Jones index

When was Eiger BioPharmaceuticals the previous earnings report?

No data

When does Eiger BioPharmaceuticals earnings report?

Next earnings report date is not announced yet